Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2029 in symptomatic polycystic liver disease
2023-505313-24-00Phase 3Authorised
- Sponsor
- Camurus
- Start
- Sep 2022
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in Polycystic liver disease (PLD) comparing CAM2029 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 53 in height-adjusted total liver volume. Planned start Sep 2022; status: authorised.
02
Drugs
octreotide hydrochloride
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on 2023-505313-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505313-24-00.